Objective To estimate the effectiveness of nirmatrelvir, compared with no treatment, in
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …

Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Background This study aims to compare the effectiveness and safety of nirmatrelvir/ritonavir
(Paxlovid) and sotrovimab for coronavirus disease 2019 (COVID-19). Methods A search was …

The availability of outpatient treatment options for COVID-19, such as nirmatrelvir-ritonavir,
remdesivir, molnupiravir, and monoclonal antibodies, raises hopes for reducing COVID-19 …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

Regardless of vaccination status, progression to severe coronavirus disease 2019 (COVID‐
19) is still a relevant cause of morbidity among immunocompromised patients. Despite the …

Background Nirmatrelvir-ritonavir is recommended for persons at risk for severe coronavirus
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …

Background: COVID-19 has been linked to the development of many post–COVID-19
conditions (PCCs) after acute infection. Limited information is available on the effectiveness …

Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …